Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy

Poitiers University Hospital

Status and phase: Completed; Phase 2

Conditions: Chronic Plaque Psoriasis

Treatments: Drug: HUMIRA 40mg

Study type: Interventional

Funder types: Other

Identifiers

NCT01872546

CYTOPSO

Details and patient eligibility

About

The expertise in the characterization of transcriptomics profile in lesional psoriatic skin and on the availability of innovative therapy for these patients.The investigators propose to follow the modification of the skin transcriptomics profile in psoriatic patients during successful Adalimumab biotherapy. Skin transcriptomics profiles of normal skin, psoriatic non lesional skin, and psoriatic lesional skin before and after biotherapy will be compared. The investigators will focus on the modification of the cytokine "signature" in these skin lesions and of some markers of keratinocyte inflammation. The modification of the transcriptomics profile induced by the biotherapy will be correlated to the clinical response Psoriasis Area and Severity Index.

Enrollment: 15 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with chronic plaque psoriasis involving at least 10% of body surface area with no previous biotherapy.
• Adalimumab prescribed in usual practice

Exclusion criteria

• Patients presenting a contraindication to the use of Adalimumab:

hypersensibility in Adalimumab or in one of the excipients.

• Patients presenting an evolutionary tuberculosis or the other severe infections such as sepsis and opportunist infections
• presenting patients one cardiac insufficiencies moderated in severe
• Patients under anakinra or abatacept
• current participation in another study of clinical research

Trial design

15 participants in 1 patient group

Adalimumab

Experimental group

Treatment:

Drug: HUMIRA 40mg